Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Trading Down 0.3 %

Shares of TENX stock opened at $3.77 on Wednesday. The firm’s 50 day moving average is $3.70 and its 200-day moving average is $3.65. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. Equities research analysts anticipate that Tenax Therapeutics will post -6.68 earnings per share for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.